Gabapentin (All indications)

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10095
R36745		 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 2.17 [1.54;3.05] C
excluded (control group) 		47/378   179/2,916 226 378
ref
S8517
R28088		 Coste (Controls unexposed, NOS) (Mixed indications), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 2.51 [1.85;3.41] C 47/378   91,455/1,710,441 91,502 378
ref
S8513
R28056		 Kilic (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Low birth weight (< 2500 g) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.29 [0.50;3.34] C
excluded (control group) 		5/72   48/876 53 72
ref
S8514
R28059		 Kilic (Controls unexposed NOS) (Mixed indications), 2014 Low birth weight (< 2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: No 2.00 [0.90;4.60]
excluded (control group) 		5/72   23,503/673,844 23,508 72
ref
S8515
R28062		 Kilic (Controls unexposed, sick) (Mixed indications), 2014 Low birth weight (< 2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 1.51 [0.60;3.77] C 5/72   249/5,275 254 72
ref
Total 2 studies 2.35 [1.68;3.29] 91,756 450
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 1 2.51[1.85; 3.41]91,50237887%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Kilic (Controls unexposed, sick) (Mixed indications), 2014Kilic, 2014 2 1.51[0.60; 3.77]2547213%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 7% 2.35[1.68; 3.29]91,7564500.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS) (Mixed indications; 2: Controls unexposed, sick) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.35[1.68; 3.29]91,7564507%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Kilic (Controls unexposed, sick) (Mixed indications), 2014 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.51[1.85; 3.41]91,502378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 unexposed, sickunexposed, sick 1.51[0.60; 3.77]25472 -NAKilic (Controls unexposed, sick) (Mixed indications), 2014 1 Tags Adjustment   - No  - No 2.35[1.68; 3.29]91,7564507%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Kilic (Controls unexposed, sick) (Mixed indications), 2014 2 Controls   - epilepsy indication  - epilepsy indication 1.51[0.60; 3.77]25472 -NAKilic (Controls unexposed, sick) (Mixed indications), 2014 1 All studiesAll studies 2.35[1.68; 3.29]91,7564507%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Kilic (Controls unexposed, sick) (Mixed indications), 2014 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8513, 8514, 10095

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.44[1.84; 3.25]115,0104500%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Kilic (Controls unexposed NOS) (Mixed indications), 2014 2 unexposed, sick controlsunexposed, sick controls 1.51[0.60; 3.77]25472 -NAKilic (Controls unexposed, sick) (Mixed indications), 2014 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.04[1.46; 2.85]2794502%NACoste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Kilic (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 20.510.01.0